Cisatracurium Besylate Injection shortage
To Be Discontinued 3 presentations · 1 manufacturers · first FDA posting 2026-05-06 · last update 2026-09-11
Manufacturers: Hospira, Inc., a Pfizer Company
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug | Posted 09/11/2026 Updated 09/11/2026 Discontinued 09/11/2026 |
| Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug | Posted 05/06/2026 Updated 05/06/2026 Discontinued 05/06/2026 |
| Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug | Posted 05/06/2026 Updated 05/06/2026 Discontinued 05/06/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)